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We systematically reviewed studies of the virological efﬁcacy of the 4 new tenofovir (TDF)-containing
regimens recommended for initial antiretroviral (ARV) therapy in the 2010 World Health Organization ARV
Treatment Guidelines. Thirty-three studies assessed the efﬁcacy of 1 or more TDF-containing regimens: TDF/
lamivudine (3TC)/nevirapine (NVP) (n 5 3), TDF/ emtricitabine (FTC)/NVP (n 5 9), TDF/3TC/efavirenz
(EFV) (n 5 6), and TDF/FTC/EFV (n 5 19). TDF/3TC/NVP was the least well-studied and appeared the least
efﬁcacious of the 4 regimens. In 2 comparative studies, TDF/3TC/NVP was associated with signiﬁcantly more
virological failure than AZT/3TC/NVP; a third study was terminated prematurely because of early virological
failure. TDF/FTC/NVP was either equivalent or inferior to its comparator arms. TDF/3TC/EFV was equivalent
to its comparator arms. TDF/FTC/EFV was equivalent or superior to its comparator arms. Possible explanations
for these ﬁndings include the greater antiviral activity of EFV versus NVP and longer intracellular half-life of
FTC-triphosphate versus 3TC-triphosphate. Further study of TDF/3TC/NVP is required before it is widely
deployed for initial ARV therapy.
The initial antiretroviral (ARV) regimens used by most
national treatment programs in resource-limited settings
include 2 nucleoside reverse-transcriptase inhibitors
(NRTIs) and 1 non-nucleoside reverse-transcriptase
inhibitor (NNRTI). The NRTIs in these regimens have
consisted of zidovudine (AZT) or stavudine (d4T) with
lamivudine (3TC); the NNRTI component has been
nevirapine (NVP) or efavirenz (EFV). The 4 regimens
created from these ARVs have saved hundreds of
thousands of lives and provided hope to millions of
others.
However, d4T mitochondrial toxicities and AZT
anemia have cast a pall on the promise of ARV therapy.
Therefore, the 2010 World Health Organization (WHO)
ARV Treatment guidelines recommend phasing out
d4T and adding 4 new options for ﬁrst-line therapy:
tenofovir (TDF)/3TC/NVP, TDF/emtricitabine (FTC)/
NVP, TDF/3TC/EFV, and TDF/FTC/EFV. TDF is more
potent and less toxic than AZT and d4T; median
decreases in plasma human immunodeﬁciency virus
(HIV)-1 RNA levels (virus load; VL) in subjects re-
ceiving TDF, AZT, or d4T monotherapy are 1.4, 0.5,
and 0.5 log10, respectively [1].
It is not known, however, whether the 4 WHO-
recommended, TDF-containing regimens are equally ef-
ﬁcacious or even whether each offers an improvement
over the older dual NRTI/NNRTI regimens. Thus, we
performed a systematic review of the virological efﬁcacy
of the 4 WHO-recommended, TDF-containing regimens.
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Search Strategy
To identify studies assessing the efﬁcacy of WHO-recommended,
TDF-containing ﬁrst-line ARV regimens, we searched for
English-language papers and meeting abstracts that included
prospective or retrospective studies of TDF/3TC/NVP, TDF/
FTC/NVP, TDF/3TC/EFV, and TDF/FTC/EFV. Searches were
conducted on 1 August 2011. We excluded studies (1) con-
taining ARV-experienced patients; (2) lacking virological ef-
ﬁcacy results; (3) containing multiple regimens for which the
number of individuals receiving each regimen was unknown;
and (4) containing 10 or fewer TDF-treated subjects (Figure 1).
Both comparative and noncomparative studies were included
in our search. The search strings and methods for identifying
and reviewing studies are described in the Supplementary text.
Data Analysis
Unless otherwise stated, standard drug dosages were used in
the studies: (1) TDF 300 mg once daily; (2) AZT 300 mg twice
daily; (3) d4T 30 or 40 mg twice daily; (4) 3TC 150 mg twice
daily or 300 mg once daily; (5) FTC 200 mg once daily; (6) NVP
200 mg once daily for a 2-week lead-in period and then as
200 mg twice daily; and (7) EFV 600 mg once daily.
Treatment and virological failure were generally deﬁned ac-
cording to each study’s criteria. Treatment failure was usually
deﬁned as failure to meet a prespeciﬁed level of virological
suppression, regardless of whether the cause was study drop-
out, death, nonadherence, or drug toxicity. Virological failure
was usually deﬁned as treatment failure due to virologic non-
response or rebound.
Genotypic drug resistance was deﬁned as the emergence of
a mutation known to reduce ARV susceptibility including
(1) NNRTI-resistance mutations; (2) M184V, which primarily
decreases susceptibility to 3TC and FTC; (3) K65R, which de-
creases susceptibility to each of the NRTIs except AZT; and
(4) thymidine analog mutations, which decrease susceptibility
to AZT and d4T, and, to a lesser degree, TDF, didanosine, and
abacavir. Because K65R is the most important TDF-resistance
mutation, we emphasized this mutation in the text.
For studies meeting inclusion criteria, we extracted study
design, number of subjects, baseline median CD4 and VL,
protocol-deﬁned treatment and virological failure, and drug
resistance data if available. For the comparative studies, we
computed the relative risks (RRs) and 95% conﬁdence inter-
vals (CIs) for treatment and virological failure of the TDF-
containing regimen versus its comparator regimen. Signiﬁcance
was determined using 2-tailed Fisher’s exact test.
For studies in which additional data were needed, study
authors were contacted. For example, the authors of the
Nigerian PEPFAR cohort abstracts initially aggregated patients
receiving TDF/3TC/NVP and TDF/FTC/NVP [2, 3]. Upon
our request, the authors agreed to re-analyze the data so that
patients receiving TDF/3TC/NVP and TDF/FTC/NVP were
presented separately. Treatment failures included patients with
virological failure, death, lost to follow-up, transfer, withdrawal,
or medication switch without viral load support. Patients who
switched between 3TC and FTC were excluded from analysis.
RESULTS
Our literature search yielded 363 publications and 1427 con-
ference abstracts. In a preliminary screen, 206 publications were
identiﬁed and read to determine whether they met study in-
clusion criteria (Figure 1). Of these, 34 publications met study
criteria: TDF/3TC/NVP (3 studies), TDF/FTC/NVP (9 studies),
TDF/3TC/EFV (6 studies), and TDF/FTC/EFV (19 studies). Three
studies contained more than one of these regimens [2, 3, 4, 5],
and 1 study was described in 2 separate abstracts [2, 3].
Tables 1–4 summarize the study designs, subject character-
istics, and outcome measures for each of the studies. Figure 2
displays the RR and 95% CI of treatment and virological
failure for the comparative studies. Studies containing compar-
isons between a TDF-containing regimen and regimens con-
taining non–US Food and Drug Administration (FDA)–approved
ARVs or ARV combinations that have never been recom-
mended by the US Department of Health and Human Services
(DHHS) or WHO are shown in Tables 1–4, but not Figure 2.
The following section reviews the main ﬁndings for each of
the 4 regimens.
TDF/3TC/NVP
The efﬁcacy of TDF/3TC/NVP for initial ARV therapy was as-
sessedin3studies(Table1):(1)theDAUFINtrial,anopen-label
randomized controlled trial (RCT) of 71 subjects receiving
TDF/3TC/NVP once daily or AZT/3TC/NVP twice daily [6];
(2) a retrospective PEPFAR cohort study of Nigerian patients
receiving ﬁrst-line ART including TDF/3TC/NVP (n 5 285),
TDF/FTC/NVP (n 5 1852), TDF/FTC/EFV (n 5 1330), and
AZT/3TC/NVP (n 5 5925) [2, 3]; and (3) a pilot trial of
TDF/3TC/NVP once daily in 23 US subjects [7].
The DAUFIN trial was prematurely terminated because by
week 12, signiﬁcantly more subjects receiving TDF/3TC/NVP
experienced virological failure (9 of 36; 25%) than subjects re-
ceiving AZT/3TC/NVP (1 of 35; 3%; P 5 .01) [6]. Moreover,
8 of 9 TDF/3TC/NVP recipients with virological failure deve-
loped NRTI and NNRTI resistance mutations, including 6 with
K65R. No baseline characteristics appeared to explain the dif-
ferences in outcomes between the 2 treatment arms.
The Nigerian PEPFAR cohort study compared virological
outcomes of the ARV regimens administered in 4 clinics be-
tween 2006 and 2007 [2, 3]. Virological failure was signiﬁcantly
HIV/AIDS d CID 2012:54 (15 March) d 863more common in patients receiving TDF/3TC/NVP (22 of
103; 21%) compared with AZT/3TC/NVP (207 of 2174; 10%,
P , .001) and TDF/FTC/EFV (40 of 386; 10%, P , .001) but
not with TDF/FTC/NVP (104 of 646; 16%, P 5 .20). Although
baseline CD4 and VL were similar among TDF and AZT re-
cipients, patients with anemia or hepatitis B were more likely
to receive a TDF-containing regimen. The similar virological ef-
ﬁcacies of TDF/FTC/EFV, AZT/3TC/NVP (and AZT/3TC/EFV)
Figure 1. Summary of search results. A, Search results from online journal and trial databases; B, search results from conference abstracts.
A description of the online databases and conferences can be found in the Supplementary Material. Definitions: ''Duplicate publication'': Multiple
publications arising from the same study or patient cohort. ''No virologic outcome'': No virologic endpoints were available in the publication or abstract.
''Regimen or unclear or did not include regimen of interest'': Incomplete description of which antiretroviral (ARV) regimens were used, or failure to
correlate specific ARVregimens with virologic data. ''Rx experienced or simplification'': Study subjects were either (1) treatment experienced, (2) included
a mix of treatment naive and treatment experienced patients, or (3) virologically suppressed at baseline and received a tenofovir (TDF)-regimen as
simplification. ''Sample size'': Study included 10 or fewer patients. ''Non-English'': Study was only published in a foreign language.
864 d CID 2012:54 (15 March) d HIV/AIDSTable 1. Studies of Tenofovir/Lamivudine/Nevirapine for Initial Antiretroviral Therapy
Reference
a Study Design (VL Endpoint) Regimen No. CD4 VL Weeks
Rx
Failure
b VF
c VF P Value
d Genotypic Resistance Testing
DAUFIN [6] Prospective OL randomized
trial (VL .2 log10 Y by wk 12
and ,400 through wk 96)
TDF/3TC/NVP (QD) 36 191 5.0 12 15 (42%) 9 (25%) Prematurely terminated by wk 12. Eight
subjects with VF on TDF/3TC/NVP got GRT.
All developed NRTI 1 NNRTI DRMs
including 6 with 65R. The AZT/3TC/NVP
subject had no DRMs.
AZT/3TC/NVP (BID) 35 195 4.9 12 11 (31%) 1 (3%) .01
Nigerian
PEPFAR [2, 3]
Retrospective cohort study
(VL ,1000 at wk 24)
TDF/3TC/NVP (BID) 285 132 4.6 48 126 (44%) 22/103 (21%) NA
TDF/FTC/NVP (BID) 1852 137 4.7 48 761 (41%) 104/646 (16%) .20
TDF/FTC/EFV 1330 136 4.7 48 552 (41%) 40/386 (10%) .005
AZT/3TC/NVP (BID) 5925 147 4.6 48 1998 (34%) 207/2174 (10%) ,.001
Boehringer-
Ingelheim [7]
Prospective OL pilot trial
(VL ,75 at wk 24)
TDF/3TC/NVP (QD) 23 169 5.2 24 13 (57%) 7 (30%) — Prematurely terminated because of the high
rate of VF, which occurred in 7of 8 subjects
with baseline VL $100 000. The 7 subjects
with VF had NRTI 6 NNRTI DRMs. 65R
occurred in 1 subject.
Abbreviations: AZT, zidovudine; BID, twice daily; CD4, CD41 cells/mm
3; DRMs, drug resistance mutations; FTC, emtricitabine; GRT, genotypic resistance testing; NA, not available; NNRTI, non-nucleoside
reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; OL, open-labeled; QD, once daily; TDF, tenofovir; VL, virus load in RNA log10 copies/ml; wk, week; 3TC, lamivudine.
a Reference: The Nigerian PEPFAR study results are also presented in Tables 2 and 4.
b Rx Failure: Treatment failure deﬁned as the proportion of subjects failing to achieve virological success according to the authors’ intention-to-treat analysis. For the Nigerian PEPFAR study, patients with missing data
were excluded from this analysis.
c VF: Virological failure deﬁned as treatment failure due to virologic nonresponse or rebound. VF calculated as (number of subjects with VF)/(total number of subjects), unless the authors used a different deﬁnition
(in which case authors’ numbers are shown).
d VF P value: P values comparing virological failure in TDF/3TC/NVP vs comparator arm.
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Reference
a Study Design (VL Endpoint) Regimen No. CD4 VL Weeks Rx Failure
b VF
c VF P Value
d Genotypic Resistance Testing
Brescia
University [8]
Prospective randomized
trial (VLY 1log by wk 12)
TDF/FTC/NVP (BID) 7 132 5.1 12 5 (71%) 3 (42%) 3 TDF/FTC/NVP subjects with VF had
NRTI 1 NNRTI DRMs including
1 with 65R.
TDF/FTC/ATVr (QD) 7 190 5.1 12 0 (0%) 0 (0%) .19
ARTEN [9] Prospective OL randomized
trial (VL,50 at wk 48)
TDF/FTC/NVP (QD
and BID arms)
376 182 5.1 48 125 (33%) 44 (12%) 29 of 44 subjects in combined NVP arms
had NRTI 6 NNRTI DRMs including
12 with 65R. No ATVr subjects had
DRMs.
TDF/FTC/ATVr (QD) 193 188 5.1 48 67 (35%) 28 (15%) .35
NEWART [10] Prospective OL randomized
trial (VL,50 at wk 48)
TDF/FTC/NVP (BID) 75 176 4.9 48 29 (39%) 11 (15%) 7of 9 NVP subjects with GRT had
NRTI 6 NNRTI DRMs, including
5 with ‘‘reduced response’’ to TDF.
0 of 9 ATV/r subjects with GRT had
DRMs.
TDF/FTC/ATVr (QD) 77 193 4.9 48 27 (35%) 12 (16%) ..5
VERxVE [11] Prospective randomized
trial (VL,50 at wk 48)
TDF/FTC/NVP IR (BID) 506 227 4.7 48 122 (24%) 30 (6%) 31 of 54 NVP IR subjects with GRT had
NRTI 6 NNRTI DRMs including 7 with
65R. 19 of 32 NVP XR subjects had
NRTI 6 NNRTI DRMs including
7 with 65R
TDF/FTC/NVP XR (QD) 505 229 4.7 48 96 (19%) 16 (3%) .05
OCTANE
Trial 2 [12]
Prospective OL randomized
trial (VL ,400 at wk 24)
TDF/FTC/NVP (BID) 249 121 5.2 72 34 (14%) 29 (12%) NA
TDF/FTC/LPVr (BID) 251 121 5.2 72 36 (14%) 32 (13%) ..5
DAYANA [4] Prospective OL randomized
trial (VL,50 at wk 48)
TDF/FTC/NVP (BID) 31 200 5.4 48 7 (23%) 3/27 (11%) No subjects with VF in the TDF/FTC/NVP
and TDF/FTC/EFV arms had DRMs.
3 of 6 subjects with VF in TDF/LPV/r
arm had PI DRMs. 1 of 3 subjects with
VF in TDF/FTC/AZT arm had 184V and
TAMS
TDF/FTC/EFV (QD) 30 200 5.4 48 7 (30%) 3/25 (12%) ..5
TDF/LPV/r (QD) 29 200 5.4 48 12 (59%) 6/18 (33%) .13
TDF/FTC/AZT 29 200 5.4 48 5 (17%) 3/27 (11%) ..5
Nigerian
PEPFAR [2, 3]
Retrospective cohort study
(VL ,1000 at wk 24)
TDF/FTC/NVP (BID) 1852 137 4.7 48 761 (41%) 104/646 (16%) NA
TDF/3TC/NVP (BID) 285 132 4.6 48 126 (44%) 22/103 (21%) .20
TDF/FTC/EFV 1330 136 4.7 48 552/1330 (41%) 40/386 (10%) .01
AZT/3TC/NVP (BID) 5925 146 4.6 48 1998 (34%) 207/2174 (10%) ,.001
Frankfurt
Cohort [5]
Retrospective cohort study
(VL,50 at wk 48)
TDF/FTC/NVP (BID) 72 201 4.8 48 23 (32%) 10 (13%) NA
TDF/FTC/EFV 77 208 5.1 48 16 (21%) 6 (8%) .29
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Sin the PEPFAR cohort [3] suggests that the decreased viro-
logical efﬁcacy of TDF/3TC/NVP and TDF/FTC/NVP versus
the AZT regimens is less likely to be due to sicker patients
receiving TDF.
In the TDF/3TC/NVP pilot trial, 7 of 23 subjects (30%)
developed virological failure, including 5 with NRTI and/or
NNRTI resistance [7]. Like the DAUFIN trial, this trial was
prematurely terminated because of frequent early virological
failure.
Among the 15 subjects receiving TDF/3TC/NVP who under-
went genotypic resistance testing, 7 (47%) developed K65R.
TDF/FTC/NVP
The efﬁcacy of TDF/FTC/NVP for initial ARV therapy was
assessed in9 studies (Table 2).Fiveprospective [4, 8–10, 12]a n d
2 retrospective studies [2, 5] compared TDF/FTC/NVP to an-
other regimen. An 8th prospective study compared the recently
FDA-approved extended-release (XR) form of NVP with stan-
dard NVP in combination with TDF/FTC [11]. There was also
a single-arm retrospective study of TDF/FTC/NVP [13].
Three large comparative trials reported that the virological
efﬁcacy of TDF/FTC/NVP was similar to that of TDF/FTC plus
ATV/r (ARTEN [9] and NEWART [10]) or LPV/r (OCTANE
Trial 2) [12]( Figure 2). However, in the ARTEN and OCTANE
trials, signiﬁcantly more subjects discontinued the NVP arm
than the boosted-protease inhibitor (PI) arm.
In contrast, TDF/FTC/NVP was less efﬁcacious than AZT/
3TC/NVP and TDF/FTC/EFV in the Nigerian PEPFAR cohort
[2, 3]. In addition, a small RCT was terminated prematurely
because 3 of 7 (42%) subjects receiving TDF/FTC plus NVP
twice daily had early virological failure and resistance compared
with 0 of 7 receiving TDF/FTC/ATV/r once daily (P 5 .2) [8].
The VERxVE trial demonstrated a small increased risk of vi-
rological failure withTDF/FTC/NVP twice daily (30 of 506;6%)
compared with TDF/FTC/NVP XR once daily (16 of 505; 3%;
P 5 .05) [11]. Fifty-ﬁve subjects discontinued the study
during the NVP lead-in phase and were not included in the
randomization.
Among 112 subjects receiving TDF/FTC/NVP who under-
went genotypic resistance testing, 23 (21%) developed the
NRTI-resistance mutation K65R (Table 2).
TDF/3TC/EFV
The efﬁcacy of TDF/3TC/EFV for initial ARV therapy was as-
sessed in 5 RCTs [14–16, 18, 19] and 1 retrospective cohort[17].
In the comparative studies, there were no statistically signiﬁcant
differences between TDF/3TC/EFV and its comparator arms,
which included d4T/3TC/EFV, ddI/3TC/EFV, AZT/3TC/EFV,
TDF/3TC/RAL, and AZT/3TC/LPV/r (Figure 2)[ 15–19]. Among
63 subjects receiving TDF/3TC/EFV who underwent genotypic
resistance testing, 16 (25%) developed K65R (Table 3).
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HIV/AIDS d CID 2012:54 (15 March) d 867Table 3. Studies of Tenofovir/Lamivudine/Efavirenz for Initial Antiretroviral Therapy
Reference Study Design (VL Endpoint) Regimen No. CD4 VL Weeks Rx Failure
a VF
b VF P Value
c Genotypic Resistance Testing
GS-903 [14] Prospective randomized
trial (VL ,400 at wk 48)
TDF/3TC/EFV 299 276 4.9 48 60 (20%) 29 (10%) Of 29 TDF subjects with GRT, 16 had $1 NNRTI DRM,
12 had 184V, and 7 had 65R. Of 25 d4T subjects with
GRT, 12 had $1 NNRTI DRM, 8 had 184V, 2 had 65R
d4T/3TC/EFV 301 283 4.9 48 48 (16%) 25 (8%) ..5
Merck-004 [15] Prospective randomized
trial (VL ,50 at wk 48)
TDF/3TC/EFV 38 280 4.8 48 5 (13%) 1 (3%) The EFV subject with GRT had $1 NNRTI DRM,
184V, 65R. Two RAL subjects with GRT had $1 RAL
DRM and 184V.
TDF/3TC/RAL (BID) 160 305 4.8 48 23 (14%) 5 (3%) ..5
TEDAL [16] Prospective randomized
trial (VL ,50 at wk 48)
TDF/3TC/EFV 64 203 5.3 48 21 (33%) 8 (13%) All 27 subjects with VF had NRTI and/or NNRTI DRMS.
5 TDF/3TC/EFV subjects had 65R
DDI/3TC/EFV 72 172 5.4 48 19 (26%) 6 (8%) ..5
DDI/ABC/EFV 63 183 5.3 48 29 (46%) 13 (21%) .24
Parkland [17] Retrospective cohort study
(VL ,400 at wk 48)
TDF/3TC/EFV 163 NA 4.8 48 NA 28 (17%) NA
AZT/3TC/EFV 313 NA 4.5 48 NA 56 (18%) ..5
SISTHER
Substudy [18]
Prospective randomized
trial (VL ,50 at wk 52)
TDF/3TC/EFV 83 194 5.3 28 26 (30%) NA 2 of 5 subjects TDF/3TC/EFV with GRT had 65R. No
DRMs occurred with AZT/3TC/LPV/r
AZT/3TC/LPV/r (BID) 91 194 5.3 28 32 (38%) NA ..5
Elvucitabine
Phase II trial [19]
Prospective randomized
trial (VL ,50 at wk 48)
TDF/3TC/EFV 37 325 4.8 96 8 (22%) 1/30 (3%) The EFV and ELV subjects with VF each had $1 NNRTI
DRM. The EFV subject also had 184V
TDF/ELV/EFV (QD) 37 325 4.8 96 13 (35%) 1/25 (4%) ..5
Abbreviations: AZT, zidovudine; BID, twice daily; CD4, CD41 cells/mm
3; d4T, stavudine; DDI, didanosine; DRMs, drug resistance mutations; EFV, efavirenz; ELV, elvucitabine (an investigational NRTI); GRT, genotypic
resistance testing; LPVr, ritonavir-boosted lopinavir; NA, not available; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; QD, once daily; RAL, raltegravir; TDF, tenofovir;
VL, virus load in RNA log10 copies/ml; wk, week; 3TC, lamivudine.
a Rx Failure: Treatment failure deﬁned as proportion of subjects failing to achieve virological success according to the authors’ intention-to-treat analysis.
b VF: Virological failure deﬁned as treatment failure due to virologic nonresponse or rebound. VF calculated as (number of subjects with VF)/(total number of subjects), unless the authors used a different deﬁnition
(in which case authors’ numbers are shown).
c VF P value: P values comparing virological failure in TDF/3TC/EFV vs comparator arm. If no VF results are available, P value for Rx Failure is given.
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STable 4. Studies of Tenofovir/Emtricitabine/Efavirenz for Initial Antiretroviral Therapy
Reference
a Study Design (VL Endpoint) Regimen
b No. CD4 VL Weeks Rx Failure
b VF
c VF P Value
d Genotypic Resistance Testing
GS-934 [20] Prospective randomized
trial (VL ,400 at wk 48)
TDF/FTC/EFV 244 233 5.0 48 38 (16%) 12 (5%) 9 of 12 subjects with VF on TDF/FTC/EFV
had DRMs. 9 had NNRTI DRMs, 2 had
184V, none had 65R. 17 of 23 subjects
on AZT/3TC/EFV with VF had DRMs.
16 had NNRTI DRMs, 7 had 184V
AZT/3TC/EFV 243 241 5.0 48 66 (27%) 23 (9%) .06
STARTMRK [21] Prospective randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV 282 217 5.0 48 52 (18%) 39 (14%) Of 39 subjects with VF on TDF/FTC/EFV,
3 had NNRTI-DRMs and 1 had 184V.
Of the 27 with VF on TDF/FTC/RAL
4 had RAL-DRMs and 3 had 184V
TDF/FTC/RAL 281 219 5.0 48 40 (14%) 27 (10%) .15
ACTG 5202 [22] Prospective randomized
trial (VL ,200 at wk 24)
TDF/FTC/EFV 464 234 4.7 48 97 (21%) 57 (12%) Of 57 subjects with VF on TDF/FTC/EFV,
27 had NNRTI DRMs, 5 had 184V and
4 had 65R. Of the 72 subjects with VF
on ABC/3TC/EFV, 41 had NNRTI DRMs,
22 had 184V and 3 had 65R. Of the
57 subjects with VF on TDF/FTC/ATV/r,
5 had NNRTI DRMs. Of 83 subjects on
ABC/3TC/ATV/r, 11 had 184V
ABC/3TC/EFV 465 225 4.7 48 132 (28%) 72 (15%) .16
TDF/FTC/ATV/r 465 224 4.7 48 101 (23%) 57 (12%) ..5
ABC/3TC/ATV/r 463 236 3.6 48 125 (27%) 83 (18%) .02
ASSERT [23] Prospective randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV 193 230 5.1 48 56 (29%) 2 (1%) No subjects on TDF/FTC/EFV had DRMs.
Of 6 subjects with VF on ABC/3TC/EFV,
3 had NNRTI-DRMs, and 1 had 65R
ABC/3TC/EFV 192 240 5.0 48 78 (41%) 6 (3%) .17
ALTAIR [24] Prospective randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV 114 227 4.7 48 17 (10%) 4 (4%) Of 4 subjects with VF on TDF/FTC/EFV,
1 had NNRTI and 1 had 184V DRMs.
Of 11 subjects with VF on TDF/FTC/
AZT/ABC, 2 had DRMs, including
1 with 65R and 1 with 184V 1 a TAM.
Of 4 subjects with VF on TDF/FTC/
ATV/r 1 had 184V
TDF/FTC/ATV/r 105 235 4.8 48 12 (8%) 4 (4%) ..5
TDF/FTC/AZT/ABC 103 226 4.6 48 28 (24%) 11 (11%) .06
ACTG 5175
(PEARLS) [25]
Prospective randomized
trial (VL ,400 at wk 48)
TDF/FTC/EFV 526 162 5.0 48 68 (13%) NA NA
AZT/3TC/EFV 519 169 5.1 48 78 (15%) NA ..5
DAYANA [4] Prospective OL randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV (QD) 30 200 5.4 48 7 (30%) 3/25 (12%) No subjects with VF in the TDF/FTC/NVP
and TDF/FTC/EFV arms had DRMs.
3 of 6 subjects with VF in TDF/LPV/r
arm had PI DRMs. 1 of 3 subjects with
VF in TDF/FTC/AZT arm had 184V and
TAMS
TDF/FTC/NVP (BID) 31 200 5.4 48 7 (23%) 3/27 (11%) ..5
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Reference
a Study Design (VL Endpoint) Regimen
b No. CD4 VL Weeks Rx Failure
b VF
c VF P Value
d Genotypic Resistance Testing
TDF/LPV/r (QD) 29 200 5.4 48 12 (59%) 6/18 (33%) .13
TDF/FTC/AZT 29 200 5.4 48 5 (17%) 3/27 (11%) ..5
Advanz-3 [26] Prospective OL randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV 28 48 5.1 48 7 (25%) 4 (14%) NA
TDF/FTC/ATV/r 30 32 5.5 48 8 (27%) 1 (3%) .19
TDF/FTC/LPV/r 29 30 5.1 48 13 (45%) 4 (14%) ..5
ECHO [27] Prospective randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV 344 257 5.0 48 59 (17%) 19 (6%) Of 19 subjects with VF on TDF/FTC/EFV,
8 had NNRTI and 4 had 184V. Of
45 subjects with VF on TDF/FTC/
TMC278, 26 had NNRTI, 26 had 184V
and 3 had K65R DRMs
TDF/FTC/RPV 346 240 5.0 48 59 (17%) 45 (13%) .001
QUAD Study [28] Prospective randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV 23 436 4.58 48 1 (5%) 0 No genotypic resistance reported
EVG/COBI/TDF/FTC 48 354 4.59 48 2 (4%) 0 ..5
Lersiverine
Phase IIb [29]
Prospective randomized
trial (VL ,50 at wk 48)
TDF/FTC/EFV 63 310 4.7 48 9 (14%) 1 (2%) The subject with VF receiving EFV had
K103N. 4 of 9 LRV subjects had other
NNRTI DRMs
TDF/FTC/LRV
500 mg
65 310 4.7 48 14 (21%) 5 (8%) .21
TDF/FTC/LRV
750 mg
65 310 4.7 48 14 (21%) 4 (6%) .37
CCTG 589 [30] Prospective OL pilot trial
(VL ,50 at wk 48)
TDF/FTC/EFV 25 296 4.7 48 7 (28%) 3 (12%) NA
RAL/LPV/r 26 369 4.7 48 12 (46%) 3 (12%) ..5
Acute HIV [31] Prospective single arm
trial (VL ,50 at wk 48)
TDF/FTC/EFV 61 541 5.2 48 6/41 (15%) 1/41 (2%) — NA
Nigerian
PEPFAR
d [2, 3]
Retrospective cohort study
(VL ,1000 at week 24,
conﬁrmed by wk 48)
TDF/FTC/EFV 1330 136 4.7 48 552/1330 (41%) 40/386 (10%) NA
TDF/3TC/NVP (BID) 285 132 4.6 48 126 (44%) 22/103 (21%) .005
TDF/FTC/NVP (BID) 1852 137 4.7 48 761 (41%) 104/646 (16%) .01
AZT/3TC/NVP (BID) 5925 147 4.6 48 1998 (34%) 207/2174 (10%) ..5
ANRS Senegal [32] Prospective pilot trial
(VL ,50 at wk 48)
TDF/FTC/EFV 40 111 5.3 48 11(28%) 7 (17%) — NA
Frankfurt Cohort
a [5] Retrospective cohort
study (VL ,50 at wk 48)
TDF/FTC/EFV (QD) 77 208 5.1 48 16 (21%) 6 (8%) NA
TDF/FTC/NVP (BID) 72 201 4.8 48 23 (32%) 10 (13%) .29
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The efﬁcacy of TDF/FTC/EFV was assessed in 12 prospective
trials [4, 20–29, 31], 5 retrospective studies [3, 5, 33–35], and
2 pilot trials [30, 32]. In 4 comparative studies, TDF/FTC/EFV
was associated with decreased virological failure compared with
1 or more of its comparator arms (Figure 2). In the phase III
GS-934 trial, TDF/FTC/EFV demonstrated a trend towards de-
creased virological failure compared with AZT/3TC/EFV having
an RR 5 0.5 (95% CI, .3–1.0; P 5 .06). In the phase III ECHO
trial, TDF/FTC/EFV was associated with signiﬁcantly decreased
virological failure compared with TDF/FTC/RPV having an
RR 5 0.4 (95% CI, .2–.7; P 5 .001). In A5202, TDF/FTC/EFV
was associated with signiﬁcantly decreased virological failure
compared with ABC/3TC/ATV/r. In the PEPFAR study, TDF/
FTC/EFV was associated with signiﬁcantly decreased virological
failure compared with TDF/3TC/NVP and TDF/FTC/NVP but
not AZT/3TC/NVP. In no study was TDF/FTC/EFV inferior
to a comparator arm. Among 141 subjects receiving TDF/
FTC/EFV who underwent genotypic resistance testing, 4 (3%)
developed K65R.
DISCUSSION
The 2009 DHHS ARV Treatment Guidelines (http://www.
aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?GuidelineID5
7&ClassID51, last acccessed 1 August 2011) classify TDF/3TC/
NVP and TDF/FTC/NVP as ‘‘regimens that may be accept-
able but should be used with caution.’’ Our study provides
a comprehensive analysis that supports this recommendation
and provides insight into the relative efﬁcacies of each of
the 4 WHO-recommended TDF-containing regimens.
TDF/3TC/NVP once daily was inferior to AZT/3TC/NVP in
a small European RCT, which was prematurely terminated due
to early virological failure [6]. A pilot trial of TDF/3TC/NVP
once daily was also terminated prematurely because 7 of the ﬁrst
23participants experienced early virological failure and drug
resistance [7]. The Nigerian PEPFAR study found an increased
risk of virological failure with TDF/3TC/NVP twice daily in
comparison with AZT/3TC/NVP and TDF/FTC/EFV [2, 3].
TDF/3TC/NVP is the least well-studied of the regimens, and
to our knowledge there are no ongoing studies of this regimen
(http://www.clinicaltrials.gov, last accessed 1 August 2011).
TDF/FTC/NVP appeared to be as efﬁcacious as its compar-
ator regimens in 4 of 7 studies [4, 9, 10, 12]. However, this
regimen was inferior to AZT/3TC/NVP and TDF/FTC/EFV in
the Nigerian PEPFAR study [2, 3] and to TDF/FTC/NVP XR
in the VERxVE study [11]. In addition, increased early viro-
logical failure led to premature study discontinuation in a small
prospective study [8]. In contrast, TDF/3TC/EFV and TDF/
FTC/EFV were consistently as efﬁcacious as their comparator
regimens.
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NEWART [10] TDF/FTC/ ATV/r 1.1 0.7 1.7
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TEDAL [16] ddI/3TC/EFV 1.2 0.7 2.1
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Risk
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Advanz 3 [25] TDF/FTC/ATV/r 0.5 0.2 1.0
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Figure 2. Relative risk (RR) and 95% confidence interval (CI) for treatment and virological failure in comparative studies: RR and 95% CI for studies
comparing TDF/3TC/NVP, TDF/FTC/NVP, TDF/3TC/EFV, and TDF/FTC/EFV to another regimen are depicted. Regimens containing non-US Food and Drug
872 d CID 2012:54 (15 March) d HIV/AIDSAmong patients with virological failure on a TDF-containing
regimen, the NRTI-resistance mutation K65R emerged fre-
quently with TDF/3TC/NVP, less frequently with TDF/FTC/
NVP or TDF/3TC/EFV, and rarely with TDF/FTC/EFV. In the
following sections, we summarize published studies on the
ARV activity and pharmacokinetics of NVP compared with
EFV, and 3TC compared with FTC, to determine whether
differences among these ARV pairs might explain the relative
efﬁcacies of the TDF-containing regimens.
ARV Activity and Pharmacokinetics of EFV and NVP
EFV is more potent in vitro than NVP against both wild-type and
drug-resistant HIV-1 variants. In cell culture, EFV EC50sa r e.50-
fold lower than those of NVP (reviewed in [36]). In biochemical
assays, EFV IC50sa r e.25-fold lower than those of NVP [36].
Most NNRTI-resistance mutations also reduce NVP susceptibility
more than EFV susceptibility (Supplementary Table 2).
In the 2 largest RCTs that compared EFV- and NVP-con-
taining initial ARV regimens, virological failure was higher in
subjects receiving NVP [37, 38]. The 2NN trial randomized 1216
patients to 4 arms containing d4T/3TC plus NVP once daily vs
NVP twice daily vs EFV once daily vs EFV 1 NVP once daily.
There was no difference in the proportion of virological failures
in the NVP once and twice daily arms. Virological failure in the
pooled NVP arms (265 of 607, 43.7%) was signiﬁcantly higher
than in the EFV arm(151of400,37.8%;P 5 .02). Inthe NNRTI
substudy of the FIRST trial, 228 subjects were randomized to
NVP or EFV with 2 NRTIs (n 5 110) or 2 NRTIs plus a PI
(n 5 118) [38]: virological failure was signiﬁcantly higher in the
NVP (54 of 117, 46%) vs EFV arms (33 of 111, 23%; P , .02).
EFV has been associated with signiﬁcantly decreased viro-
logical failure relative to NVP in multiple large retrospective
studies, including a large South African study of 2817 sub-
jects, and 2 studies in the United States and United Kingdom
containing a total of 1414 subjects [39–41].
D e s p i t ew i d ei n t e r i n d i v i d u a lpharmacokinetics, both EFV
and NVP have steady-state plasma half-lives usually ex-
ceeding 20 hours (Viramune Package Insert, http://www.
boehringer-ingelheim.com/products/prescription_medicines/
hiv_aids.html; Sustiva Package Insert http://www.bms.
com/products/Pages/prescribing.aspx, last accessed 1 May
2011). NVP administered 400 mg once daily or 200 mg twice
daily were similarly efﬁcacious in the2NN and ARTEN studies,
although the 400 mg daily dose may be associated with an
increase in toxicity [37, 42] and lower NVP trough levels
[43]. These attributes of daily NVP may have been contrib-
uted to the higher treatment failure in the DAUFIN and
Boehringer-Ingelheim studies [6, 7], particularly if drug
dosages were frequently missed.
ARV Activity and Pharmacokinetics of 3TC and FTC
3TC and FTC are oxathiolane-cytosine analogs that selectively
inhibit HIV replication. Like other NRTIs, 3TC and FTC must
be triphosphorylated intracellularly before they can competi-
tively inhibit endogenous deoxycytidine triphosphate (dCTP)
and cause chain termination. The chemical structures of 3TC
and FTC differ only by the presence in FTC of ﬂuorine at the
5’-position of its cytosine ring. Several studies suggest that
FTC may have greater ARV activity than 3TC, with the EC50
of FTC 3-fold–10-fold lower than 3TC in cell culture (reviewed
in [44]). However, the most clinically relevant difference may
be the difference in intracellular half-lives between 3TC-TP
and FTC-TP. The intracellular half-life of 3TC-TP appears to
be shorter and more variable than that of intracellular FTC-TP:
6–30 hours [45] compared with approximately 36–39 hours
[46]. Decreased intracellular half-life of 3TC-TP vs FTC-TP
would potentially make 3TC-containing regimens more sus-
ceptible to individual missed drug doses, particularly when
paired with other ARVs with relatively short half-lives.
ARV Regimens Are More Than the Sum of Their Parts
The possible inferiority of TDF/3TC/NVP compared with AZT/
3TC/NVP despite the greater ARV activity and lower toxicity
of TDF compared with AZT underscores the concept that
ARV regimens are more than the sum of their parts. This was
illustrated several years ago in an analogous scenario in which
the majority of subjects in several studies receiving TDF/3TC/
ABC for initial ARV therapy developed virological failure and
drug resistance within 12 weeks [47, 48]. In contrast, AZT/3TC/
ABC—a regimen that was once an alternative regimen for
initial ARV therapy—was rarely associated with early virological
failure (Supplementary Figure 1). The cross-resistance engen-
dered by K65R to TDF, 3TC, and ABC is likely to have been
a contributing factor because this mutation emerged in ap-
proximately one-half of the TDF/3TC/ABC virological failures.
Whether the higher virological failure rate of TDF/3TC/
NVP also results from a low-genetic barrier to resistance is
not known for certain. K65R emerged frequently with TDF/
3TC/NVP, less frequently with TDF/FTC/NVP or TDF/3TC/
EFV, and rarely with TDF/FTC/EFV. Therefore, the risk of
Figure 2 continued. Administration-approved antiretrovirals (ARVs) or ARV combinations are not shown. RR for prospective studies are depicted as black
points, and RR for retrospective studies are depicted as gray points. Points to the left of midline represent improved virological efficacy for the tenofovir
(TDF)-containing regimen. Points to the right of midline represent improved virological efficacy for the comparator regimen. Abbreviations: AZT, zidovudine;
3TC, lamivudine; ABC, abacavir; ATV/r, boosted atazanavir; ddI, didanosine; EFV, efavirenz; FTC, emtricitabine; LPV/r, boosted lopinavir; NVP, nevirapine;
NVP XR, extended-release nevirapine; RAL, raltegravir; RPV, rilpivirine; TDF, tenofovir.
HIV/AIDS d CID 2012:54 (15 March) d 873K65R emergence may be diminished by the substitution of
EFV for NVP, and possibly by FTC for 3TC. However, both
treatment and virological failure are multifactorial, and it
would be an oversimpliﬁcation to attribute the differences
among these 4 regimens solely to their vulnerability to an
individual mutation.
CONCLUSIONS
Many countries are in the process of revising their national
guidelines to reﬂect the WHO 2010 Treatment Guidelines.
TDF/3TC/NVP will be increasingly used, because it is likely
to be the least costly of the 4 WHO-recommended, TDF-
containing regimens. However, if TDF/3TC/NVP is associated
with a higher failure rate, this will rapidly lead to escalating
costs because of the increased need for second-line therapy.
Because patients in resource-limited regions undergo less fre-
quent laboratory monitoring and are at higher risk of develo-
ping drug resistance than patients in well-resourced regions
[49], further study of TDF/3TC/NVP is urgently required
before this regimen is widely deployed for initial ARV therapy.
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